2017 Annual Meeting of the American Association for Cancer Research

Using a “double whammy” of 2 HER2-directed therapies achieved a clinical benefit rate of 70% and an objective response rate (ORR) of 30% in patients with heavily pretreated, HER2-positive metastatic colorectal cancer (CRC), according to final results from the phase 2 HERACLES-A trial.
CAR T-cell therapy achieved excellent responses in an updated report on a series of 50 patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) treated with CAR T-cells at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City.
The novel combination of the investigational IDO pathway inhibitor indoximod plus pembrolizu­mab led to higher response rates in patients with advanced melanoma than what is seen with pembrolizumab alone, according to interim analysis of a phase 2 clinical trial reported at the 2017 Annual Meeting of AACR.
Preliminary data show excellent and durable responses to atezolizumab in 10% of women with triple-negative breast cancer (TNBC), one of the most aggressive and difficult cancers to treat.

Results 1 - 4 of 4

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code